Cargando…

Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area

PURPOSE: Lactate dehydrogenase (LDH), which was an indirect marker of hypoxia, was a potentially prognostic factor in several malignancies. There is a lack of evidence about the prognostic value of serum LDH level in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment from hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Mu-xing, Zhao, Hong, Bi, Xin-yu, Li, Zhi-yu, Yao, Xue-song, Li, Huai, Huang, Zhen, Han, Yue, Zhou, Jian-guo, Zhao, Jian-jun, Zhang, Ye-fan, Zhao, Dong-bin, Cai, Jian-qiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349941/ https://www.ncbi.nlm.nih.gov/pubmed/27880930 http://dx.doi.org/10.18632/oncotarget.13428

Ejemplares similares

The Mechanisms of HBV-Induced Hepatocellular Carcinoma
por: Jiang, Yu, et al.
Publicado: (2021)

Lactate Dehydrogenase Is an Important Prognostic Indicator for Hepatocellular Carcinoma after Partial Hepatectomy()()
por: Zhang, Jing-Ping, et al.
Publicado: (2015)

Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area
por: Wei, Zhengbo, et al.
Publicado: (2014)

Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area
por: Yu, Jeong Il, et al.
Publicado: (2017)

HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing
por: Liu, Lijuan, et al.
Publicado: (2023)

Epidemiology of Hepatitis C Virus Infection in Highly Endemic HBV Areas in China
por: Li, Duan, et al.
Publicado: (2013)

NAD-Independent L-Lactate Dehydrogenase Is Required for L-Lactate Utilization in Pseudomonas stutzeri SDM
por: Gao, Chao, et al.
Publicado: (2012)

The Structural Basis of Babesia orientalis Lactate Dehydrogenase
por: Yu, Long, et al.
Publicado: (2022)

Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma
por: Chen, Peng, et al.
Publicado: (2019)

Astrocytic lactate dehydrogenase A regulates neuronal excitability and depressive-like behaviors through lactate homeostasis in mice
por: Yao, Shan, et al.
Publicado: (2023)

Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
por: Zhang, Yafei, et al.
Publicado: (2012)

Impact of lactate dehydrogenase on prognosis of patients undergoing cardiac surgery
por: Zeng, Yu, et al.
Publicado: (2022)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
por: Kong, Fan-Hua, et al.
Publicado: (2021)

Lactate Dehydrogenase A Governs Cardiac Hypertrophic Growth in Response to Hemodynamic Stress
por: Dai, Chongshan, et al.
Publicado: (2020)

Identification and functional characterization of Lys-trimethylation of lactate dehydrogenase A
por: Li, Lin, et al.
Publicado: (2019)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment
por: Yu, Yaping, et al.
Publicado: (2014)

Differentiating between tuberculous and non-tuberculous pleural effusions using the pleural fluid ratio of 10× adenosine deaminase/lactate dehydrogenase
por: Li, Yan, et al.
Publicado: (2023)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients
por: Chen, Zhan-hong, et al.
Publicado: (2018)

Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study
por: Chang, Te-Sheng, et al.
Publicado: (2022)

Altered expression of lactate dehydrogenase and monocarboxylate transporter involved in lactate metabolism in broiler wooden breast
por: Zhao, Dan, et al.
Publicado: (2019)

Genomic DNA methylation profiling indicates immune response following thermal ablation treatment for HBV-associated hepatocellular carcinoma
por: Zhao, Yanan, et al.
Publicado: (2020)

Prognostic Role of Glasgow Prognostic Score in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Li, Mu-xing, et al.
Publicado: (2015)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

A mechanistic kinetic description of lactate dehydrogenase elucidating cancer diagnosis and inhibitor evaluation
por: Tang, Peifeng, et al.
Publicado: (2017)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

The neutrophil-to-lymphocyte ratio and lactate dehydrogenase combined in predicting liver metastasis and prognosis of colorectal cancer
por: Chen, Qin, et al.
Publicado: (2023)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Variants Identified by Hepatocellular Carcinoma and Chronic Hepatitis B Virus Infection Susceptibility GWAS Associated with Survival in HBV-Related Hepatocellular Carcinoma
por: Li, Cong, et al.
Publicado: (2014)

HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway
por: Zhao, Baoxin, et al.
Publicado: (2023)

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma
por: Xue, Miao, et al.
Publicado: (2020)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk
por: Liu, Shi, et al.
Publicado: (2022)

Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

Association of CD44 polymorphisms and susceptibility to HBV‐related hepatocellular carcinoma in the Chinese population
por: Deng, Yan, et al.
Publicado: (2019)

Serum hepatitis B virus (HBV) DNA levels at different stages of clinical course in patients with chronic HBV infection in an endemic area.
por: Heo, Jeong, et al.
Publicado: (2003)

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection
por: Chen, Jian-Lin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qkq2nqm8icsh8et0udh8dajra0